BAYER TO PRESENT XARELTO DATA FROM EINSTEIN TRIALS IN DEC. (ENG)

     (The following press release from Bayer was received by e-mail. It was not 
confirmed by the sender.) 
News-Release 
Not intended for U.S. and UK Media: 54th American Society of Hematology
(ASH) Annual Meeting and Exposition 2012:
New data on Bayer’s Xarelto® (Rivaroxaban) as a Single-Drug Solution for
the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
Pooled data from EINSTEIN trials show oral rivaroxaban has an improved
benefit-risk profile and lower rates of major bleeding compared with
standard therapy / New data also show reduced hospital stay and improved
patient-reported satisfaction with rivaroxaban for patients with acute
symptomatic PE 
Berlin, Germany, November 30, 2012 - Bayer HealthCare announced today that
new data from the clinical development programme for its oral anticoagulant
Xarelto® (rivaroxaban) will be presented at the 54th American Society of
Hematology (ASH) Annual Meeting and Exposition in Atlanta, GA, USA,
December 8-11, 2012. These data underscore the benefits of rivaroxaban for
patients at risk of dangerous blood clots across multiple venous
thromboembolic conditions. 
Notable data analyses to be presented at ASH 2012 include: 
• Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism: 
A Pooled Analysis of the EINSTEIN DVT and EINSTEIN PE Studies
https://ash.confex.com/ash/2012/webprogram/Paper51556.html
o     Oral Presentation: Session 332. Antithrombotic Therapy I; 12:15
o     Saturday, December 8, 2012; 12:00 - 13:30; Georgia World Congress
Center, B405-B407 
• Patient-Reported Treatment Satisfaction with Oral Rivaroxaban versus
Standard Therapy in the Treatment of Acute Symptomatic Pulmonary Embolism
https://ash.confex.com/ash/2012/webprogram/Paper51526.html
o     Poster Session: Session 332. Antithrombotic Therapy: Poster I
o     Saturday, December 8, 2012; 17:30 - 19:30; Georgia World Congress
Center, Hall B1-B2 
• Reduction in Initial Length of Stay with Rivaroxaban Single-Drug Regimen
versus LMWH-VKA Standard of Care: Findings from the EINSTEIN Trial Program
https://ash.confex.com/ash/2012/webprogram/Paper51519.html
o     Poster Session: Session 332. Antithrombotic Therapy: Poster III
o     Monday, December 10, 2012; 18:00 - 20:00; Georgia World Congress
Center, Hall B1-B2 
The pivotal EINSTEIN Clinical Trial Programme comprises three Phase III
studies evaluating rivaroxaban alone versus the dual-drug regimen of low
molecular weight heparin (LMWH) and vitamin K antagonist (VKA) in the
treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and
the prevention of recurrent DVT and PE. 
Xarelto has been approved as a single-drug solution for the treatment of
DVT and PE as well as the prevention of recurrent DVT and PE in adults in a
number of countries worldwide including Europe and the U.S. 
About Xarelto® (Rivaroxaban)
Rivaroxaban is the most broadly indicated new oral anticoagulant and is
marketed under the brand name Xarelto®. To date, Xarelto is approved for
use in the following venous arterial thromboembolic (VAT) indications: 
• The prevention of stroke and systemic embolism in adult patients with
non-valvular atrial fibrillation (AF) with one or more risk factors
• The treatment of deep vein thrombosis (DVT) and prevention of recurrent
DVT and pulmonary embolism (PE) in adults
• The treatment of PE and prevention of recurrent DVT and PE in adults
• The prevention of venous thromboembolism (VTE) in adult patients
undergoing elective hip or knee replacement surgery 
Whilst licences may differ from country to country, across all indications
Xarelto is approved in more than 120 countries. 
Rivaroxaban was discovered by Bayer HealthCare, and is being jointly
developed with Janssen Research & Development, LLC. Xarelto is marketed
outside the U.S. by Bayer HealthCare and in the U.S. by Janssen
Pharmaceuticals, Inc. (a Johnson & Johnson Company). 
Anticoagulant medicines are potent therapies used to prevent or treat
serious illnesses and potentially life threatening conditions. Before
initiating therapy with anticoagulant medicines, physicians should
carefully assess the benefit and risk for the individual patient. 
Responsible use of Xarelto is a high priority for Bayer, and the company
has developed a Prescribers Guide for physicians and a Xarelto Patient Card
for patients to support best practice. 
To learn more, please visit: https://prescribe.xarelto.com
To learn more about thrombosis, please visit
http://www.thrombosisadviser.com
To learn more about Xarelto, please visit http://www.xarelto.com 
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields
of health care, agriculture and high-tech materials. Bayer HealthCare, a
subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one
of the world’s leading, innovative companies in the healthcare and medical
products industry and is based in Leverkusen, Germany. The company combines
the global activities of the Animal Health, Consumer Care, Medical Care and
Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop,
manufacture and market products that will improve human and animal health
worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec
31, 2011) and is represented in more than 100 countries. More information
at http://www.healthcare.bayer.com. 
Our online press service is just a click away:
http://press.healthcare.bayer.com 
Find more information at http://www.bayerpharma.com. 
Forward-Looking Statements
This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management.
Various known and unknown risks, uncertainties and other factors could lead
to material differences between the actual future results, financial
situation, development or performance of the company and the estimates
given here. These factors include those discussed in Bayer’s public reports
which are available on the Bayer website at http://www.bayer.com. The
company assumes no liability whatsoever to update these forward-looking
statements or to conform them to future events or developments. 
Contact:
Bayer Pharma AG
Astrid Kranz, Tel. +49 30 468-12057
E-Mail: mailto:astrid.kranz@bayer.com 
This press release is available here:
http://www.baynews.bayer.de/baynews/baynews.nsf/id/2012-0545-e 
Yours BayNews Editorial Team 
Bayer AG
Communications
Building W11
51368 Leverkusen, Germany 
--------------------------------------------------- 
Further news releases you can find here: http://www.press.bayer.com
 
 
Press spacebar to pause and continue. Press esc to stop.